(RTTNews) - atai Life Sciences (ATAI) announced Friday that Perception Neuroscience's Phase 2a clinical trial of PCN -101 or R-ketamine failed to its primary endpoint of a statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback